X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA NATCO PHARMA PLETHICO PHARMA/
NATCO PHARMA
 
P/E (TTM) x -1.1 13.3 - View Chart
P/BV x 0.0 3.8 0.4% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 PLETHICO PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
NATCO PHARMA
Mar-18
PLETHICO PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs3951,080 36.6%   
Low Rs31671 4.7%   
Sales per share (Unadj.) Rs604.4592.1 102.1%  
Earnings per share (Unadj.) Rs32.5188.4 17.2%  
Cash flow per share (Unadj.) Rs51.3206.3 24.9%  
Dividends per share (Unadj.) Rs08.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs473.6833.6 56.8%  
Shares outstanding (eoy) m34.0836.90 92.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.41.5 23.8%   
Avg P/E ratio x6.64.6 141.2%  
P/CF ratio (eoy) x4.24.2 97.8%  
Price / Book Value ratio x0.51.1 42.8%  
Dividend payout %04.4 0.0%   
Avg Mkt Cap Rs m7,26232,311 22.5%   
No. of employees `000NA4.8 0.0%   
Total wages/salary Rs m1,5963,256 49.0%   
Avg. sales/employee Rs ThNM4,522.5-  
Avg. wages/employee Rs ThNM674.0-  
Avg. net profit/employee Rs ThNM1,439.0-  
INCOME DATA
Net Sales Rs m20,59821,848 94.3%  
Other income Rs m386404 95.6%   
Total revenues Rs m20,98422,252 94.3%   
Gross profit Rs m2,8189,284 30.3%  
Depreciation Rs m642662 97.0%   
Interest Rs m1,593154 1,034.5%   
Profit before tax Rs m9698,872 10.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,920 -7.2%   
Profit after tax Rs m1,1076,952 15.9%  
Gross profit margin %13.742.5 32.2%  
Effective tax rate %-14.321.6 -66.0%   
Net profit margin %5.431.8 16.9%  
BALANCE SHEET DATA
Current assets Rs m18,87721,307 88.6%   
Current liabilities Rs m11,8965,920 201.0%   
Net working cap to sales %33.970.4 48.1%  
Current ratio x1.63.6 44.1%  
Inventory Days Days3673 49.1%  
Debtors Days Days198107 185.7%  
Net fixed assets Rs m9,86114,986 65.8%   
Share capital Rs m341369 92.3%   
"Free" reserves Rs m12,33130,353 40.6%   
Net worth Rs m16,13930,760 52.5%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14637,151 89.2%  
Interest coverage x1.658.6 2.7%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.6 105.7%   
Return on assets %8.119.1 42.6%  
Return on equity %6.922.6 30.3%  
Return on capital %12.329.3 41.9%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40210,322 42.7%   
Fx outflow Rs m3,1842,978 106.9%   
Net fx Rs m1,2197,343 16.6%   
CASH FLOW
From Operations Rs m2,4374,636 52.6%  
From Investments Rs m-6,265-11,155 56.2%  
From Financial Activity Rs m2,4906,509 38.3%  
Net Cashflow Rs m-1,337-18 7,428.7%  

Share Holding

Indian Promoters % 82.7 52.0 158.9%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 4.3 7.8 54.8%  
FIIs % 5.5 16.6 33.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 26.0 28.8%  
Shareholders   10,665 25,395 42.0%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   STERLING BIOTECH  SANOFI INDIA  DR. DATSONS LABS  ORCHID PHARMA LTD  NOVARTIS  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 250 Points Up; Tata Motors & Power Grid Top Gainers(12:30 pm)

Stock markets in India are presently trading higher. The BSE Sensex is trading higher by 252 points and the NSE Nifty is trading higher by 59 points.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS